QuantumCell ApS
Key figures
- Return on assets
- -27.9%
- Return on equity
- -29.7%
- Current ratio
- 816.4%
- Equity ratio
- 87.8%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | -8,168,872 |
Operating profit | -8,781,173 |
Finance income | 133,166 |
Finance expenses | 771,406 |
Tax expense | -1,227,017 |
Profit/loss for the year | -8,192,396 |
Employees
| Reporting period | |
|---|---|
Avg. employees | 1 |
Personnel costs | 612,301 DKK |
Balance sheet
| Reporting period | |
|---|---|
Cash and cash equivalents | 29,244,272 |
Current assets | 31,312,888 |
Non-current assets | 111,632 |
Total assets | 31,424,520 |
Equity | 27,589,252 |
Liabilities | 3,835,268 |
Current liabilities | 3,835,268 |
Working capital
| Reporting period | |
|---|---|
Other current receivables | 762,553 |
Trade payables | 2,164,512 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 638,100 |
Retained earnings | 26,951,152 |
Investments and assets
| Reporting period | |
|---|---|
Long-term investments and receivables | 111,632 |
Annual report highlights
Business and development
The principal activities of the Company is to conduct research, development, and commercialization of pharmaceuticals and other related business activities.
The Company is incorporated 7 June 2025 and hence the financial statements for 2025 covers the period 7 June - 31 December 2025.
During 2025, the Company incorporated a US subsidiary, QuantumCell Inc.
The income statement for 2025 shows a loss of DKK 8,192,396, and the balance sheet at 31 December 2025 shows equity of DKK 27,589,252.
During 2025, the Company completed capital increases of 556 thousand shares and total proceeds of DKK 36,458 thousand before transactions costs, DKK 758 thousand, which has been offset directly through retained earnings.
Risks and material matters
Management has considered whether conditions and events exist that, when considered inaggregate, raise significant doubt about the Company’s ability to continue as a going concern through oneyear from the balance sheet date.
Cash at 31 December 2025 amount to DKK 29,244 thousand. The Company’s current liquidity is expected to fund planned activities into July 2026; however, additional financing will be required to support operations beyond. Management and the Board are pursuing funding options to address this. As these plans are subject to factors outside the Company’s control, a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern.
The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. Therefore, the financial statements have been prepared on the assumption that the company will continue as a going concern and with the expectation of realizing assets and settling liabilities and commitments in the normal course of business.
Going concern
Management has considered whether conditions and events exist that, when considered inaggregate, raise significant doubt about the Company’s ability to continue as a going concern through oneyear from the balance sheet date.…
No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.
Commitments and security
The Company has not provided any security or other collateral in assets at 31 December 2025.